Skip to main content

Newsroom press releases

01/12/22 - 18:30

2023 Annual Calendar of Corporate Events (288 KB)
Other
Download

09/11/22 - 7:04

DiaSorin Simplexa® cCMV Direct assay received U.S. FDA 510(K) clearance (134.99 KB)
Products Molecular
Download

07/11/22 - 7:12

DiaSorin commercializes molecular reagent for monkeypox virus (149 KB)
Products Molecular
Download

27/10/22 - 13:44

Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards (316.32 KB)
Financial Data
Download

05/10/22 - 6:37

DiaSorin furthers its collaboration with BARDA for the LIAISON® NES (160.31 KB)
Products Molecular
Download

14/09/22 - 0:29

DIASORIN SIMPLEXA™ COVID-19 TEST RECEIVED U.S. FDA 510(K) CLEARANCE (194.22 KB)
Products Molecular
Download

03/08/22 - 12:26

Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards (316.69 KB)
Financial Data
Download

14/07/22 - 20:00

DiaSorin receives FDA 510(k) clearance for its LIAISON® MeMed BV® test (160.88 KB)
Products Immunodiagnostic
Download

07/06/22 - 18:06

Execution of the project for the redefinition of the corporate structure of DiaSorin (286.22 KB)
Other
Download

20/05/22 - 7:08

DiaSorin CE Marks their ARIES® Flu A/B & RSV+SARS-CoV-2 Lowplex Assay (106.16 KB)
Products Molecular
Download

09/05/22 - 7:02

DiaSorin and B·R·A·H·M·S, part of Thermo Fisher Scientific, partner to develop and commercialize the new LIAISON® B·R·A·H·M·S MR-proADM™ (173.49 KB)
Acquisition / Partnership
Download

06/05/22 - 17:33

Update 2022 Annual Calendar of Corporate Events (285.68 KB)
Financial Disclosures
Download

06/05/22 - 16:45

Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards (467.24 KB)
Financial Data
Download

02/05/22 - 12:55

Publication of the summary report of the votes cast (280.95 KB)
Financial Disclosures
Download

29/04/22 - 16:26

Shareholders' meeting 2022 (166.12 KB)
Other
Download

22/04/22 - 12:37

New proposal for resolution related to the remuneration of the Board of Statutory Auditors (281.82 KB)
Financial Disclosures
Download

13/04/22 - 16:43

DiaSorin: Publication of the updated proxy forms for voting through the Designated Representative (282.86 KB)
Financial Disclosures
Download

08/04/22 - 19:13

Publication of the lists of candidates for the appointment of the Board of Directors, the Board of Statutory Auditors and relevant proposals for resolution (291.36 KB)
Financial Disclosures
Download

08/04/22 - 9:53

Update annual calendar of corporate events 2022 (288.09 KB)
Financial Disclosures
Download

05/04/22 - 9:51

Notice pursuant to art. 144-octies, paga 2 of Consob Regulation No. 11971/1999 (309.07 KB)
Other
Download

04/04/22 - 18:12

Filing of the lists submitted by IP Investimenti e Partecipazioni S.r.l. (577.98 KB)
Other
Download

16/03/22 - 17:39

DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021 (404.69 KB)
Financial Data
Download

08/03/22 - 7:13

DiaSorin announces CE Marking of the new NxTAG® Gastrointestinal Molecular Multiplex Pathogen Panel (105.47 KB)
Products Molecular
Download

13/01/22 - 7:24

DiaSorin releases an updated Simplexa™ SARS-CoV-2 Variants Direct molecular assay (RUO) for the detection of mutations associated with the Omicron variant (486.67 KB)
Products Molecular
Download

21/12/21 - 11:07

2022 Annual Calendar of Corporate Events (296.13 KB)
Other
Download

16/12/21 - 22:47

DiaSorin 2022-2025 Strategic Plan (552.15 KB)
Financial Data
Download

30/11/21 - 19:10

DiaSorin confirms effectiveness of its Molecular Diagnostic tests in light of new Omicron SARS-CoV-2 Variant (307.83 KB)
Products Molecular
Download

29/11/21 - 7:06

DiaSorin receives FDA approval for its LIAISON® QuantiFERON®-TB Gold Plus assay for use on the LIAISON® XS Analyzer (437.79 KB)
Products Immunodiagnostic
Download

23/11/21 - 7:10

DiaSorin launches LIAISON® MeMed BV®, the first high throughput blood test to differentiate between bacterial and viral infections, in countries accepting the CE Mark (412.77 KB)
Products Immunodiagnostic
Download

11/11/21 - 16:56

DiaSorin business momentum and the Luminex acquisition drive Revenues and Profitability up in the first 9 months of 2021 (862.48 KB)
Financial Data
Download

05/11/21 - 11:22

Weekly report treasury shares buy-back (2.15 MB)
Other
Download

02/11/21 - 20:00

Conclusion treasury shares buy-back plan (294.67 KB)
Other
Download

02/11/21 - 19:57

Weekly report treasury shares buy-back (3.5 MB)
Other
Download

27/10/21 - 16:35

Issuance of the "Physical Settlement Notice" (517.5 KB)
Other
Download

07/10/21 - 11:45

Publication of the summary report of the votes (290.08 KB)
Other
Download

04/10/21 - 12:27

The Extraordinary Shareholders' Meeting of DiaSorin authorizes the convertibility of the equity-linked bond and the share capital increase (297.73 KB)
Other
Download

18/09/21 - 8:16

DiaSorin CE Marks its new Simplexa™ COVID-19 & Flu A/B Direct Assay for Detection and Differentiation of SARS-CoV-2 and Influenza in One Test (407.21 KB)
Products Molecular
Download

30/07/21 - 18:43

Start up of the treasury shares buy-back plan (773.96 KB)
Other
Download

30/07/21 - 12:57

DiaSorin: Revenues and Profitability continue upward momentum in the First Half of 2021, with Guidance raised following the acquisition of Luminex (774.36 KB)
Financial Data
Download

22/07/21 - 18:28

Publication of Information Document under the provisions of the art. 71 of the CONSOB Regulation n. 11971/1999 (303.95 KB)
Other
Download

14/07/21 - 15:05

DiaSorin announces completion of the Acquisition of Luminex Corporation (566.52 KB)
Acquisition / Partnership
Download

09/07/21 - 7:34

DiaSorin obtains all approvals necessary to complete the acquisition of Luminex (560.68 KB)
Acquisition / Partnership
Download

21/06/21 - 18:49

The Shareholders’ meeting of Luminex Corporation approved the merger of Luminex with a U.S. wholly-owned subsidiary of DiaSorin (395.62 KB)
Acquisition / Partnership
Download

15/06/21 - 6:56

DiaSorin launches the first fully automated CLIA high-throughput solution for diagnosing Hepatitis E (307.58 KB)
Products Immunodiagnostic
Download

07/06/21 - 15:16

Communication on total amount of voting rights (563.42 KB)
Other
Download

03/06/21 - 7:47

DiaSorin signs agreements with Unifarma and Alliance Healthcare for the distribution in Italian pharmacies of the LIAISON® IQ (523.42 KB)
Acquisition / Partnership
Download

25/05/21 - 7:03

DiaSorin: launch of the LIAISON® Quick Detect COVID Ag assay, an antigen test to detect COVID-19 infection (402.64 KB)
Products Immunodiagnostic
Download

21/05/21 - 7:02

DiaSorin Releases an Assay for Rapid Identification of Mutations Associated with Circulating Variants of SARS-CoV-2 (393.69 KB)
Products Molecular
Download

20/05/21 - 8:27

DiaSorin’s LIAISON® SARS-CoV-2 TrimericS IgG test receives FDA Emergency Use Authorization for the U.S. market (506.2 KB)
Products Immunodiagnostic
Download

14/05/21 - 16:10

DiaSorin: significant growth in Revenues and Profitability in the first quarter 2021 (756.07 KB)
Financial Data
Download

28/04/21 - 17:46

DiaSorin successfully prices its offer of € 500 million Senior Unsecured Equity-Linked Bonds due 2028 (529.64 KB)
Financial Data
Download

28/04/21 - 7:54

DiaSorin announces its intention to offer € 500 million senior unsecured equity-linked bonds due 2028 (563.02 KB)
Financial Data
Download

22/04/21 - 15:58

Shareholders' meeting April 22, 2021 (422.91 KB)
Other
Download

21/04/21 - 7:02

DiaSorin, in partnership with QIAGEN, launches the new LIAISON® LymeDetect® Assay based on QuantiFERON technology (621.42 KB)
Products Immunodiagnostic
Download

20/04/21 - 18:58

DiaSorin launches the LIAISON® IQ with a first test that detects IgG antibodies against SARS-COV-2 in markets accepting the CE Mark (403.5 KB)
Products Immunodiagnostic
Download

14/04/21 - 10:05

Communication voting rights amount (544.6 KB)
Other
Download

12/04/21 - 11:08

Weekly report treasury shares buy-back (914.42 KB)
Other
Download

11/04/21 - 19:47

DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion (569.09 KB)
Acquisition / Partnership
Download

06/04/21 - 8:53

Start up buy-back plan (774.02 KB)
Other
Download

06/04/21 - 7:06

DiaSorin announces its strategic collaboration with Lumos Diagnostics (438.14 KB)
Acquisition / Partnership
Download

30/03/21 - 7:01

DiaSorin received BARDA funding to develop and achieve FDA regulatory authorization, for its LIAISON® SARS-CoV-2 Ag test (661.47 KB)
Products Immunodiagnostic
Download

29/03/21 - 7:02

DiaSorin has obtained FDA Emergency Use Authorization for its LIAISON® SARS-CoV-2 Ag for COVID-19 testing in the U.S. (494.1 KB)
Products Immunodiagnostic
Download

11/03/21 - 16:37

Dividend coupon date correction (414.99 KB)
Financial Data
Download

11/03/21 - 15:31

Revenues, Profitability and Cash Flow Generation hit record highs in 2020 (748.06 KB)
Financial Data
Download

23/02/21 - 6:11

DiaSorin obtained FDA approval for two additional serology tests for Lyme Disease in the U.S. market (413.92 KB)
Products Immunodiagnostic
Download

27/01/21 - 18:50

2021 Annual Calendar of Corporate Events (209.87 KB)
Other
Download

11/01/21 - 18:43

DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 TrimericS IgG test (418.29 KB)
Products Immunodiagnostic
Download
Price Sensitive

eMarket SDIR System and eMarket STORAGE
For the dissemination and the storage of Regulated Information, DiaSorin S.p.A. uses the eMarket SDIR circuit and the eMarket STORAGE mechanism (available at the address www.emarketstorage.it), managed by Teleborsa S.r.l., with registered office in Piazza di Priscilla, 4, Rome, Italy.